A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis

• Status: Not yet recruiting
• Trial end date: 2024-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the impact of the probiotic Lactobacillus rhamnosus (LGG) on proton pump inhibitor (PPI)-induced changes to the microbes that live in the gastrointestinal tract and are passed out in the stool. PPI medicines reduce stomach acid and are commonly used to treat acid reflux disease.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Omeprazole

Criteria

Inclusion Criteria:

• Individuals on an unrestricted regular diet with no dietary restrictions (vegan, low FODMAP, gluten free, dairy-free etc) or other fad diets (e.g., keto, intermittent fasting, etc.).

• Healthy subjects will be screened for current or chronic GI symptoms using a 16-item questionnaire.

• Only those with an absence of symptoms will eligible to participate.

Exclusion Criteria:

• For healthy volunteers, will include prior surgery altering the esophagus, stomach, and intestine (except appendectomy).

• Chronic daily use of medications affecting GI secretion or motor function.

• The presence of any GI-motility affecting systemic diseases or untreated psychiatric disease.

• Pregnancy.